Guanylyl cyclase-A inhibits angiotensin II type 2 receptor-mediated pro-hypertrophic signaling in the heart

Endocrinology

Volumn 150, Issue 8, 2009, Pages 3759-3765

  Li, Yuhao ^a,f   Saito, Yoshihiko ^b   Kuwahara, Koichiro ^a   Rong, Xianglu ^a   Kishimoto, Ichiro ^c   Harada, Masaki ^a   Adachi, Yuichiro ^a   Nakanishi, Michio ^a   Kinoshita, Hideyuki ^a   Horiuchi, Masatsugu ^d   Murray, Michael ^e   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF SYDNEY   (Australia)

^f NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; NATRIURETIC PEPTIDE RECEPTOR A; OLMESARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; GENE EXPRESSION; HEART VENTRICLE HYPERTROPHY; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; BODY WEIGHT; CARDIOMEGALY; COLLAGEN; HEART; IMIDAZOLES; IMMUNOBLOTTING; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM; ORGAN SIZE; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ATRIAL NATRIURETIC FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAZOLES; VASOCONSTRICTOR AGENTS;

EID: 67651148198     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-1353     Document Type: Article

References (38)

1. Gosse P 2005 Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl 23:S27-S33
2. Nakao K, Itoh H, Saito Y, Mukoyama M, Ogawa Y 1996 The natriuretic peptide family. Curr Opin Nephrol Hypertens 5:4-11
3. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K 2000 Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 35:19-24
4. Ogawa Y, Tamura N, Chusho H, Nakao K 2001 Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol 79:723-729
5. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DL, Beuve A 1995 Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378:65-68
6. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y, Nakanishi M, Adachi Y, Garbers DL, Fukamizu A, Nakao K 2002 Guanylyl cyclase A inhibits angiotensin II type 1a receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation 106:1722-1728
7. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, Hamanaka I, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y, Nakanishi M, Adachi Y, Garbers DL, Fukamizu A, Nakao K 2004 Androgen contributes to gender-related cardiac hypertrophy and fibrosis in mice lacking the gene encoding guanylyl cyclase-A. Endocrinology 145:951-958
8. Nakanishi M, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, Kawakami R, Nakagawa Y, Tanimoto K, Yasuno S, Usami S, Li Y, Adachi Y, Fukamizu A, Garbers DL, Nakao K 2005 Role of natriuretic peptide receptor GC-A in myocardial infarction evaluated using genetically engineered mice. Hypertension 46:441-447
9. Hunyady L, Turu G 2004 The role of the AT1 angiotensin receptor in cardiac hypertrophy: angiotensin II receptor or stretch sensor? Trends Endocrinol Metab 15:405-408
10. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG 2001 Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol 281:H2337-H2365
11. Lopez JJ, Lorell BH, Ingelfinger JR, Weinberg EO, Schunkert H, Diamant D, Tang SS 1994 Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol 267:H844-H852
12. Suzuki J, Matsubara H, Urakami M, Inada M 1993 Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 73:439-447
13. Tsutsumi Y, Matsubara H, Ohkubo N, Mori Y, Nozawa Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Moriguchi Y, Shibasaki Y, Kamihata H, Inada M, Iwasaka T 1998 Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res 83:1035-1046
14. Mifune M, Sasamura H, Shimizu-Hirota R, Miyazaki H, Saruta T 2000 Angiotensin II type 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells. Hypertension 36:845-850
15. Senbonmatsu T, Ichihara S Price Jr E, Gaffney FA, Inagami T 2000 Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest 106:R25-R29
16. Ichihara S, Senbonmatsu T, Price Jr E, Ichiki T, Gaffney FA, Inagami T 2001 Angiotensin type 2 receptor is essential for ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 104:346-351
17. Yan X, Price RL, Nakayama M, Ito K, Schuldt AJ, Manning WJ, Sanbe A, Borg TK, Robbins J, Lorell BH 2003 Ventricular-specific expression of angiotensin II type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic mice. Am J Physiol Heart Circ Physiol 285:H2179-H2187
18. D'Amore A, Black MJ, Thomas WG 2005 The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 46:1347-1354
19. 2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Hypertension 41:963-967
20. 1 receptor-knockout mice. J Am Soc Nephrol 13:1162-1171
21. Akishita M, Iwai M, Wu L, Zhang L, Ouchi Y, Dzau VJ, Horiuchi M 2000 Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 102:1684-1689
22. de Bold AJ, Bruneau BG, Kuroski de Bold ML 1996 Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 31:7-18
23. Masaki H, Kurihara T, Yamaki A, Inomata N, Nozawa Y, Mori Y, Murasawa S, Kizima K, Maruyama K, Horiuchi M, Dzau VJ, Takahashi H, Iwasaka T, Inada M, Matsubara H 1998 Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest 101:527-535
24. Inagami T, Senbonmatsu T 2001 Dual effects of angiotensin II type 2 receptor on cardiovascular hypertrophy. Trends Cardiovasc Med 11:324-328
25. Oliviéro P, Chassagne C, Kolar F, Adamy C, Marotte F, Samuel JL, Rappaport L, Ostadal B 2000 Effect of pressure overload on angiotensin receptor expression in the rat heart during early postnatal life. J Mol Cell Cardiol 32:1631-1645
26. Rosenkranz S 2004 TGF-β1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63:423-432
27. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T 2002 TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109:787-796
28. Scott L, Kerr A, Haydock D, Merrilees M 1997 Subendothelial proteoglycan synthesis and transforming growth factor β distribution correlate with susceptibility to atherosclerosis. J Vasc Res 34:365-377
29. Jones ES, Black MJ, Widdop RE 2004 Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol 37:1023-1030
30. Brassard P, Amiri F, Schiffrin EL 2005 Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries. Hypertension 46:598-606
31. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG 2001 Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol 281:H2337-H2365
32. Kim S, Iwao H 2000 Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52:11-34
33. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD 2002 Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 90:135-142
34. Nakayama T, Soma M, Takahashi Y, Rehemudula D, Kanmatsuse K, Furuya K2000 Functional deletion mutation of the 5′-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res 86:841-845
35. Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L, Manunta P, Marchitti S, Venturelli V, Bianchi G, Volpe M, Stella P 2006 Association of atrial natriuretic peptide and type A natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 48:499-505
36. Usami S, Kishimoto I, Saito Y, Harada M, Kuwahara K, Nakagawa Y, Nakanishi M, Yasuno S, Kangawa K, Nakao K 2008 Association of CT dinucleotide repeat polymorphism in the 5′-flanking region of the guanylyl cyclase (GC)-A gene with essential hypertension in the Japanese. Hypertens Res 31:89-96
37. Tsutamoto T, Kanamori T, Wada A, Kinoshita M 1992 Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. J Am Coll Cardiol 20:541-546
38. Tsutamoto T, Kanamori T, Morigami N, Sugimoto Y, Yamaoka O, Kinoshita M 1993 Possibility of down-regulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 87:70-75